{"Title": "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia", "Year": 2017, "Source": "New Engl. J. Med.", "Volume": "376", "Issue": 9, "Art.No": null, "PageStart": 836, "PageEnd": 847, "CitedBy": 616, "DOI": "10.1056/NEJMoa1609783", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85014771892&origin=inward", "Abstract": "Copyright \u00a9 2017 Massachusetts Medical Society.BACKGROUND Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects. METHODS In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standardof-care chemotherapy. The primary end point was overall survival. RESULTS Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients) or chemotherapy (134 patients), 376 patients received at least one dose. Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group (hazard ratio for death with blinatumomab vs. chemotherapy, 0.71; 95% confidence interval [CI], 0.55 to 0.93; P = 0.01). Remission rates within 12 weeks after treatment initiation were significantly higher in the blinatumomab group than in the chemotherapy group, both with respect to complete remission with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hematologic recovery (44% vs. 25%, P<0.001). Treatment with blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month estimates, 31% vs. 12%; hazard ratio for an event of relapse after achieving a complete remission with full, partial, or incomplete hematologic recovery, or death, 0.55; 95% CI, 0.43 to 0.71; P<0.001), as well as a longer median duration of remission (7.3 vs. 4.6 months). A total of 24% of the patients in each treatment group underwent allogeneic stem-cell transplantation. Adverse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients in the chemotherapy group. CONCLUSIONS Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B-cell precursor ALL.", "AuthorKeywords": null, "IndexKeywords": ["Adolescent", "Adult", "Aged", "Aged, 80 and over", "Antibodies, Bispecific", "Antineoplastic Agents", "Combined Modality Therapy", "Female", "Humans", "Male", "Middle Aged", "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma", "Sepsis", "Stem Cell Transplantation", "Survival Analysis", "Transplantation, Homologous", "Young Adult"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85014771892", "SubjectAreas": [["Medicine (all)", "MEDI", "2700"]], "AuthorData": {"7202247267": {"Name": "Kantarjian H.", "AuthorID": "7202247267", "AffiliationID": "60015023", "AffiliationName": "Department of Leukemia, University of Texas M.D. Anderson Cancer Center"}, "7401758711": {"Name": "Stein A.", "AuthorID": "7401758711", "AffiliationID": "60007474", "AffiliationName": "City of Hope National Medical Center"}, "6602642806": {"Name": "Fleishman A.", "AuthorID": "6602642806", "AffiliationID": "60001673", "AffiliationName": "Amgen"}, "7003815241": {"Name": "Nagorsen D.", "AuthorID": "7003815241", "AffiliationID": "60001673", "AffiliationName": "Amgen"}, "56866181500": {"Name": "Zimmerman Z.", "AuthorID": "56866181500", "AffiliationID": "60001673", "AffiliationName": "Amgen"}, "55942219000": {"Name": "G\u00f6kbuget N.", "AuthorID": "55942219000", "AffiliationID": "60009308, 60007762", "AffiliationName": "Goethe University, University Hospital, Department of Medicine II"}, "7006521676": {"Name": "Horst H.A.", "AuthorID": "7006521676", "AffiliationID": "101998225", "AffiliationName": "Medical Department II"}, "7006039114": {"Name": "Br\u00fcggemann M.", "AuthorID": "7006039114", "AffiliationID": "101998225", "AffiliationName": "Medical Department II"}, "6701415960": {"Name": "Klapper W.", "AuthorID": "6701415960", "AffiliationID": "60005542", "AffiliationName": "Hematopathology Section, Lymph Node Registry University Hospital Schleswig Holstein, Campus Kiel"}, "7005180426": {"Name": "Topp M.S.", "AuthorID": "7005180426", "AffiliationID": "60032515", "AffiliationName": "Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikums W\u00fcrzburg"}, "7102396522": {"Name": "Fielding A.K.", "AuthorID": "7102396522", "AffiliationID": "60022148, 60032819", "AffiliationName": "Royal Free Hospital, University College London Cancer Institute"}, "7006521379": {"Name": "Schuh A.C.", "AuthorID": "7006521379", "AffiliationID": "60008768", "AffiliationName": "Princess Margaret Cancer Centre"}, "36966222800": {"Name": "Bergeron J.", "AuthorID": "36966222800", "AffiliationID": "60009022", "AffiliationName": "Centre Integre Universitaire de Sante, Services Sociaux de L'est de L'ile de Montreal, H\u00f4pital Maisonneuve-Rosemont"}, "7102742710": {"Name": "Ribera J.M.", "AuthorID": "7102742710", "AffiliationID": "60028462, 60023020", "AffiliationName": "ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona"}, "7201640839": {"Name": "Sanz M.A.", "AuthorID": "7201640839", "AffiliationID": "60001602", "AffiliationName": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto Carlos III"}, "8565989000": {"Name": "Wei A.", "AuthorID": "8565989000", "AffiliationID": "60019578, 60008014", "AffiliationName": "Alfred Hospital, Monash University"}, "7005981249": {"Name": "Dombret H.", "AuthorID": "7005981249", "AffiliationID": "60006467, 60002900, 60021567", "AffiliationName": "Institut Universitaire D'H\u00e9matologie, H\u00f4pital Saint-Louis (Assistance Publique-H\u00f4pitaux de Paris)"}, "16074229500": {"Name": "Thomas X.", "AuthorID": "16074229500", "AffiliationID": "60001780", "AffiliationName": "Centre Hospitalier Lyon Sud"}, "7102969595": {"Name": "Fo\u00e0 R.", "AuthorID": "7102969595", "AffiliationID": "60032350, 60023359", "AffiliationName": "Ematologia, Dipartimento di Biotecnologie Cellulari Ed Ematologia, Azienda Ospedaliera Policlinico Umberto i, Universit\u00e0 Sapienza di Roma"}, "56209332700": {"Name": "Bassan R.", "AuthorID": "56209332700", "AffiliationID": "60103321", "AffiliationName": "Azienda Unit\u00e0 Locale Socio Sanitaria, 12 Veneziana Ospedale dell Angelo"}, "7005421838": {"Name": "Rambaldi A.", "AuthorID": "7005421838", "AffiliationID": "60030318", "AffiliationName": "Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Universit\u00e0 Statale di Milano"}, "7006832861": {"Name": "Arslan \u00d6.", "AuthorID": "7006832861", "AffiliationID": "60012603", "AffiliationName": "Ankara Universitesi, Tip Fak\u00fcltesi, Cebeci Arastirma Ve Uygulama Hastanesi"}, "7005094713": {"Name": "Demirkan F.", "AuthorID": "7005094713", "AffiliationID": "60014930", "AffiliationName": "Dokuz Eyl\u00fcl \u00dcniversitesi, Tip Fak\u00fcltesi"}, "6602812937": {"Name": "Lech-Maranda E.", "AuthorID": "6602812937", "AffiliationID": "60084597, 60073843", "AffiliationName": "Instytut Hematologii i Transfuzjologii, Centrum Medyczne Ksztalcenia Podyplomowego"}, "7401873423": {"Name": "Wood B.L.", "AuthorID": "7401873423", "AffiliationID": "60033293", "AffiliationName": "University of Washington Medical Center"}, "56453943400": {"Name": "Holland C.", "AuthorID": "56453943400", "AffiliationID": "60001673", "AffiliationName": "Amgen"}}}